Skip to main content
. 2011 Apr 4;2:193–199. doi: 10.7150/jca.2.193

TABLE 1.

Targeted agents under clinical evaluation for the treatment of advanced thyroid cancer.

Compound Class Thyroid cancers
Axitinib Tyrosine Kinase Inhibitor (TKI) DTC, MTC, ATC
Motesanib Diphosphate TKI DTC
Pazopanib TKI DTC
Sorafenib TKI DTC
Sunitinib TKI DTC, MTC, ATC
Thalidomide Inhibitor of angiogenesis DTC, MTC
Lenalidomide Inhibitor of angiogenesis DTC